Výsledky vyhledávání - "Edgar Braendle"

MPN-161: A Phase I Study of TP-3654, an Oral PIM Kinase Inhibitor, in Patients with Intermediate-2 or High-Risk Primary or Secondary Myelofibrosis (MF)

Autor: Huyuan Yang, Edgar Braendle, Jian Mei, Claudia Lebedinsky, Golam Mohi, Steven L. Warner, Sujan Kabir

Publikováno v: Clinical Lymphoma Myeloma and Leukemia. 21:S355-S356

Context: MF is characterized by bone marrow fibrosis (BMF), ineffective hematopoiesis, splenomegaly, and debilitating symptoms. Expression of PIM-1 is significantly upregulated in MF hematopoietic cells, indicating that PIM-1 is a potential therapeut

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::85ce1cd449af8dfd8d8aa59f56350b87
https://doi.org/10.1016/s2152-2650(21)01821-8

Zobrazit plný text záznamu

A Phase 1 Study of TP-3654, an Orally-Delivered PIM Kinase Inhibitor, in Patients with Intermediate-2 or High-Risk Primary or Secondary Myelofibrosis

Autor: Jian Mei, Stephen P. Anthony, Golam Mohi, Edgar Braendle, Claudia Lebedinsky, Huyuan Yang

Publikováno v: Blood. 136:3-4

Background: Myelofibrosis (MF) is characterized by bone marrow fibrosis (BMF) and ineffective extramedullary hematopoiesis resulting in splenomegaly and debilitating symptoms. An activating Janus kinase 2 (JAK2) mutation (V617F) has been frequently o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::03f12fcad4af9b82225a89921d4f4ff9
https://doi.org/10.1182/blood-2020-134039

Zobrazit plný text záznamu

A Phase I Pharmacokinetic and Pharmacodynamic Study of TKI258, an Oral, Multitargeted Receptor Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors

Autor: R. Morrison, Edgar Braendle, Carla Heise, Felix Garzon, Priska Butzberger-Zimmerli, Judith A. Fox, Debashis Sarker, Dalal Jadayel, T.R. Jeffrey Evans, R. Molife, Johann S. de Bono, Sharianne Louie, C. Marriott, Natasha Aziz, Ian Judson, Maryon Hardie, Glenn C. Michelson

Publikováno v: Clinical Cancer Research. 14:2075-2081

Purpose: To determine the maximum tolerated dose (MTD) dose-limiting toxicity, and pharmacokinetic and pharmacodynamic profile of TKI258 (formerly CHIR-258). Experimental Design: A phase I dose escalating trial in patients with advanced solid tumors

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6887928bac5968eb4cea1962f1c2fe9f
https://doi.org/10.1158/1078-0432.ccr-07-1466

Zobrazit plný text záznamu

Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma

Autor: Ulrike Heider, Jessica Rademacher, Maren Mieth, Malte Peters, Lorenz Kleeberg, Peter Liebisch, Claudia Fleissner, Orhan Sezer, Christian Jakob, David R. Stover, Martin Kaiser, Romy Oberländer, Edgar Braendle

Publikováno v: European Journal of Haematology. 80:490-494

Objectives: Lytic bone disease is a hallmark of multiple myeloma (MM) and is caused by osteoclast activation and osteoblast inhibition. Secretion of Dickkopf (DKK)-1 by myeloma cells is a major factor which causes inhibition of osteoblast precursors.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d5381ccfdd719e732f96d8edfd373447
https://doi.org/10.1111/j.1600-0609.2008.01065.x

Zobrazit plný text záznamu

Postoperative resorptive and excretory capacity of the ileal neobladder

Autor: Ludwig Rinnab, Richard E. Hautmann, Edgar Braendle, Michael Straub

Publikováno v: BJU International. 95:1289-1292

Authors from Ulm have a further look at their model of orthotopic bladder replacement and particularly at the problem of mild metabolic acidosis due to proton reabsorption, which they describe as a common problem after ileal neobladder. They ascribe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea1cd21bea8afe6028873ae18074b837
https://doi.org/10.1111/j.1464-410x.2005.05521.x

Zobrazit plný text záznamu

Serum concentrations of DKK-1 decrease in patients with multiple myeloma responding to anti-myeloma treatment

Autor: Edgar Braendle, Britta Lamottke, Ulrike Heider, Jessica Rademacher, Christian Jakob, David R. Stover, Martin Kaiser, Maren Mieth, Orhan Sezer

Publikováno v: European journal of haematology. 82(1)

Lytic bone destruction is a hallmark of multiple myeloma (MM) and is because of an uncoupling of bone remodeling. Secretion of Dickkopf (DKK)-1 by myeloma cells is a major factor which causes inhibition of osteoblast precursors. In this study, the ef

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::715aa17984597fe34167c895423ce448
https://pubmed.ncbi.nlm.nih.gov/19067746

Zobrazit plný text záznamu

Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma

Autor: Martin, Kaiser, Maren, Mieth, Peter, Liebisch, Romy, Oberländer, Jessica, Rademacher, Christian, Jakob, Lorenz, Kleeberg, Claudia, Fleissner, Edgar, Braendle, Malte, Peters, David, Stover, Orhan, Sezer, Ulrike, Heider

Publikováno v: European journal of haematology. 80(6)

Lytic bone disease is a hallmark of multiple myeloma (MM) and is caused by osteoclast activation and osteoblast inhibition. Secretion of Dickkopf (DKK)-1 by myeloma cells is a major factor which causes inhibition of osteoblast precursors. So far, the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::4c972ff6a449463b7c4df4faca82083a
https://pubmed.ncbi.nlm.nih.gov/18331598

Zobrazit plný text záznamu

Molecular Testing for Response to Treatment for Chronic Myeloid Leukemia (CML) Patients: Information Available to Decision Makers on the Costs and Analytical and Clinical Validity of Alternative Approaches

Autor: Ossa Diego, Ratcliffe Mark, Peter J. Hudson, Edgar Braendle

Publikováno v: Blood. 116:4489-4489

Abstract 4489 Objectives: Several “home-brew” and commercially available BCR-ABL gene transcript molecular monitoring detection methodologies are in use for the detection of residual leukemia disease in patients with CML. However there are a larg

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7c57406d0cae1a2f852cbb7d68c10c7a
https://doi.org/10.1182/blood.v116.21.4489.4489

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání